North Carolina – Researchers at Duke University and the University of Georgia are developing a new flu vaccine.
The Duke Human Vaccine Institute (DHVI) is receiving $400 million over seven years from the National Institute of Allergy and Infectious Diseases (NIAID) to create a longer-lasting, more broadly protective vaccine compared to the current seasonal flu shot.
Duke’s funding comes from three contracts. The first contract involves conducting basic immunology and virology research to identify potential vaccine candidates. The second contract is for vaccine manufacturing, while the third contract provides funding for clinical trials.
Researchers at the University of Georgia could receive as much as $65 million over seven years from the National Institutes of Health (NIH) to also develop a better flu vaccine. The university will partner with Emory University and Georgia Tech.